Phase 4 Parkinson's Disease Trial, Recruiting NCT06316232 Sponsor: IRCCS Istituto delle Scienze Neurologiche di Bologna Condition: Parkinson's Disease
Back to Parkinsons Disease

Phase 4 Parkinson's Disease Trial, Recruiting

NCT06316232
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have Parkinson's disease and are already being treated with a deep brain stimulator (a device implanted in the brain to control movement symptoms), and it is working well to manage your movement problems such as slowness, stiffness, and tremor.
  • You experience "freezing of gait" (episodes where your feet feel stuck to the ground and you cannot move them) during your normal daily activities, even when your brain stimulator settings have been optimised, as confirmed by a specific questionnaire score (the New Freezing of Gait Questionnaire).

Who may not be able to join:

  • You are unable to walk 10 meters (about 33 feet) on your own without help.
  • Your brain stimulator settings cannot be safely increased by a small amount without causing unwanted side effects (confirm with trial site).
  • You have previously had serious side effects from higher doses of Parkinson's medication (levodopa) or increased brain stimulator intensity, such as hallucinations, psychosis, painful involuntary movements, a severe drop in blood pressure, or significant digestive problems.
  • You have been diagnosed with dementia, based on a low score on a standard memory and thinking test (called the MMSE).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Ilaria Cani, IRCCS Istituto delle Scienze Neurologiche di Bologna

Phone: 0039 051 4966959

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
IRCCS Istituto delle Scienze Neurologiche di Bologna
Registry
ClinicalTrials.gov
Start date
10 October 2023
Est. completion
31 December 2026

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Time spent with FOG during protocol

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov